12,000 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Freemont Management S.A.

Freemont Management S.A. acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 12,000 shares of the life sciences company's stock, valued at approximately $1,565,000.

A number of other large investors have also added to or reduced their stakes in the stock. UMB Bank n.a. raised its stake in shares of Illumina by 7.0% in the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company's stock worth $140,000 after purchasing an additional 88 shares during the last quarter. Integrated Advisors Network LLC raised its stake in shares of Illumina by 2.0% in the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company's stock worth $585,000 after purchasing an additional 90 shares during the last quarter. Carson Advisory Inc. raised its stake in shares of Illumina by 3.8% in the third quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company's stock worth $360,000 after purchasing an additional 102 shares during the last quarter. Institute for Wealth Management LLC. raised its stake in shares of Illumina by 4.6% in the second quarter. Institute for Wealth Management LLC. now owns 2,728 shares of the life sciences company's stock worth $285,000 after purchasing an additional 119 shares during the last quarter. Finally, Platform Technology Partners raised its stake in shares of Illumina by 4.2% in the third quarter. Platform Technology Partners now owns 3,512 shares of the life sciences company's stock worth $458,000 after purchasing an additional 141 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Price Performance

Shares of NASDAQ ILMN traded down $3.93 during mid-day trading on Thursday, reaching $142.24. The company's stock had a trading volume of 2,262,878 shares, compared to its average volume of 2,007,583. The firm has a market capitalization of $22.56 billion, a PE ratio of -14.68 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock has a fifty day moving average of $139.20 and a two-hundred day moving average of $124.10. Illumina, Inc. has a 52 week low of $92.69 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business's quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.33 earnings per share. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several recent analyst reports. Canaccord Genuity Group boosted their price target on Illumina from $130.00 to $145.00 and gave the stock a "hold" rating in a research note on Tuesday, November 5th. Daiwa America raised Illumina to a "strong-buy" rating in a report on Friday, August 16th. Stephens lifted their price objective on Illumina from $170.00 to $184.00 and gave the stock an "overweight" rating in a report on Tuesday. Robert W. Baird lifted their price objective on Illumina from $124.00 to $139.00 and gave the stock a "neutral" rating in a report on Wednesday, November 6th. Finally, Argus raised Illumina from a "hold" rating to a "buy" rating and set a $150.00 price objective for the company in a report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Illumina currently has a consensus rating of "Moderate Buy" and a consensus target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.